W-3646

N/A

Report date: 2022/08/23 20:00:44

Base Information

Drug NameW-3646
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionImmunomodulatorsImmunosuppressantsDisintegrin and metalloproteinase domain-containing protein 17 inhibitors
TargetsDisintegrin and metalloproteinase domain-containing protein 17
Therapy Area/IndicationsDiabetes Mellitus, Type 2Arthritis, RheumatoidSepsis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesWakunaga Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesWakunaga Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsDiabetes Mellitus, Type 2Arthritis, RheumatoidSepsis

Other Information

ATC CodeN/A
Related LinksN/A